Drug or intervention
Pioglitazone Clinical Trials
Studies that test Pioglitazone, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 33Multiple Sclerosis
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Background: In people with multiple sclerosis (MS), brain and cerebrospinal fluid (CSF) biomarkers indicate inflammation or disease. Researchers want to see if 4 drugs given alone or combined affect MS biomarkers.
- Trial name
- NCT03109288
- Testing
- Cilostazol, Leucovorin, Pirfenidone
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis
To determine the safety of Rezdiffra (Resmetirom) when administered alongside common prescriptions for Diabetes Metellus (Farxiga/dapagliflozin \& Actos/pioglitazone)
- Trial name
- NCT07848191
- Testing
- Rezdiffra, Resmetirom, ACTOS/pioglitazone
- Where
- 16 sites in United States
- Volunteers
- 150 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT)
Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities…
- Conditions
- Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
- Trial name
- NCT02969798
- Testing
- Dapagliflozin, Saxagliptin, Pioglitazone
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes Mellitus in Obese, Heart Failure With Preserved Ejection Fraction
Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants
Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: 1.
- Trial name
- PIOHF (NCT05838287)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes
Quantifying Hepatic Mitochondrial Fluxes in Humans
In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone
- Conditions
- Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
- Trial name
- NCT05305287
- Testing
- Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Oral Leukoplakia
Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia
This is a Phase IIa oral cavity leukoplakia study of pioglitazone 15mg and metformin 500mg BID for 12 weeks. The primary objective is to determine the clinical and histologic changes of leukoplakia from baseline following a 12…
- Trial name
- NCT05727761
- Testing
- pioglitazone-metformin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of Minnesota
Pancreatitis, Chronic, Pancreatitis, Acute
Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus
The purpose of this study is to evaluate efficacy of pioglitazone (PIO) versus empagliflozin (EMPA) to improve glycemic control in people with Chronic Pancreatitis (CP) or Recurrent Acute Pancreatitis (RAP) or Acute Pancreatitis…
- Conditions
- Pancreatitis, Chronic, Pancreatitis, Acute, Diabetes Mellitus
- Trial name
- PEP-DM (NCT06729996)
- Testing
- Pioglitazone (PIO), Empagliflozin (EMPA)
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases
Bioenergetic Effect of Pioglitazone in CLD-PH
The goal of this clinical trial is to learn about the safety and efficacy of Pioglitazone in people with Pulmonary Hypertension (PH) due to Chronic Lung Disease (CLD).
- Trial name
- NCT06336798
- Testing
- Pioglitazone 30mg, Labs
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Type1diabetes
SGLT2i, Pioglitazone, and Ketone Production in T1D
Participants are being asked to be in a research study. Scientists do research to answer important questions which might help change or improve treatment of participants disease in the future.
- Trial name
- NCT07056699
- Testing
- Dapagliflozin 10mg Tab, Pioglitazone 15 MG and 30mg
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes
SGLT2i, Pioglitazone, and Ketone Production in T2D
To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).
- Trial name
- NCT07053319
- Testing
- Empagliflozin 25 MG, Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Completed, with results posted
All –Nephrolithiasis, Uric Acid
Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss
The investigators will randomize overweight and obese iuan patients to Pio (45 mg/day, highest approved dose or placebo), WL (10% of body weight, following the established program used in the Diabetes Prevention Program), or…
- Trial name
- NCT04370093
- Testing
- Pioglitazone 45 mg, Weight Loss, Pioglitazone + Weight Loss
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Texas Southwestern Medical Center
High Altitude
Effects of Pioglitazone on Exogenous Carbohydrate Oxidation During Steady-State Exercise at High Altitude
Apparent hypoxia-induced insulin insensitivity along with alterations in glucose kinetics suggests reduction in glucose uptake by the peripheral tissue is a primary factor contributing to reductions in exogenous glucose oxidation…
- Trial name
- NCT06164665
- Testing
- Pioglitazone 15mg
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- United States Army Research Institute of Environmental Medicine
Type 2 Diabetes Mellitus
Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in combination with thiazolidinedione (pioglitazone) in patients with type 2 Diabetes for 12 weeks administration and to evaluate the…
- Trial name
- NCT01026194
- Testing
- Teneli / Teneli + pio
- Where
- Japan
- Volunteers
- 204 people
- Sponsor
- Tanabe Pharma Corporation
Alcohol Use Disorder
Effects of Pioglitazone on Stress Reactivity and Alcohol Craving
The purpose of this study is to examine the effects of pioglitazone on stress-induced relapse risk in a laboratory model and to examine the effects of pioglitazone on drinking, stress/anxiety, and alcohol craving in the natural…
- Trial name
- NCT05107765
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- The University of Texas Health Science Center, Houston
Gastroparesis
Pioglitazone for Idiopathic Gastroparesis
The principal objective of this pilot study will be to evaluate whether 8 weeks of treatment of pioglitazone will improve symptoms as measured by the Gastrointestinal Symptom Index (GCSI) in patients with Idiopathic Gastroparesis.
- Trial name
- PIOGAS (NCT04300127)
- Testing
- Pioglitazone 30 mg
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Johns Hopkins University